Focus: Pharvaris is a public-stage biotechnology company focused on small-molecule therapeutics, headquartered in Leiden, Netherlands, with a concentrated pipeline in angioedema and related conditions.
Profile data last refreshed 7h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Pharvaris to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pharvaris
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pharvaris's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development - Investor's Business Daily
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development Investor's Business Daily
Pharvaris Announces FDA Acceptance of New Drug Application - grafa.com
Pharvaris Announces FDA Acceptance of New Drug Application grafa.com
Pharvaris moves closer to bringing second oral on-demand HAE therapy to US - FirstWord Pharma
Pharvaris moves closer to bringing second oral on-demand HAE therapy to US FirstWord Pharma
FDA accepts Pharvaris NDA for oral hereditary angioedema treatment - The Pharma Letter
FDA accepts Pharvaris NDA for oral hereditary angioedema treatment The Pharma Letter
FDA accepts Pharvaris' new drug application for oral HAE attack treatment deucrictibant IR - Pluang
FDA accepts Pharvaris' new drug application for oral HAE attack treatment deucrictibant IR Pluang
Pharvaris Says FDA Accepted New Drug Application for Potential Treatment for Hereditary Angioedema Attacks - Moomoo
Pharvaris Says FDA Accepted New Drug Application for Potential Treatment for Hereditary Angioedema Attacks Moomoo
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles